Genentech patent expiration
1. Erivedge patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888364 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Nov, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9790183 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Sep, 2025
(11 months from now) | |
| US9278961 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2017 |
Drugs and Companies using VISMODEGIB ingredient
NCE-1 date: 31 January, 2016
Market Authorisation Date: 30 January, 2012
Treatment: Method of using vismodegib to treat basal cell carcinoma; Method of using vismodegib to treat cancer in a mammal
Dosage: CAPSULE
More Information on Dosage
ERIVEDGE family patents
2. Nutropin Aq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763394 | GENENTECH | Human growth hormone aqueous formulation |
Jun, 2015
(9 years ago) | |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 03 January, 2008
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NUTROPIN AQ family patents
3. Nutropin Aq Pen patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763394 | GENENTECH | Human growth hormone aqueous formulation |
Jun, 2015
(9 years ago) | |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 03 January, 2008
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NUTROPIN AQ PEN family patents
4. Nutropin Depot patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6051259 | GENENTECH | Composition for sustained release of human growth hormone |
Dec, 2012
(11 years ago) | |
| US5656297 | GENENTECH | Modulated release from biocompatible polymers |
Jul, 2014
(10 years ago) | |
| US5654010 | GENENTECH | Composition for sustained release of human growth hormone |
Aug, 2014
(10 years ago) | |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 22 December, 1999
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE
More Information on Dosage
NUTROPIN DEPOT family patents